Management of Acute Cough in Children: Where Do We Go From Here?

Area of Science:

• Pediatric Pharmacology
• Respiratory Medicine
• Public Health

Background:

• Pediatric cough and cold product safety is a long-standing concern for regulatory bodies and advocacy groups.
• Recent FDA review focused on codeine's safety for cough in children under 18, citing risks of respiratory depression and death.
• Existing data on codeine efficacy for acute pediatric cough is limited.

Purpose of the Study:

• To evaluate the safety and efficacy of various over-the-counter (OTC) cough medications for pediatric use.
• To review evidence for codeine, dextromethorphan, benzonatate, antihistamines, guaifenesin, and mucolytics in treating acute pediatric cough.
• To assess alternative treatments like honey and aromatic oils for pediatric acute cough.

Main Methods:

• Systematic review of existing literature and regulatory agency data.
• Analysis of controlled trials and clinical evidence regarding efficacy and adverse events.
• Evaluation of safety profiles, particularly respiratory depression and mortality risks.

Main Results:

• Codeine demonstrates minimal efficacy for acute pediatric cough, with significant risks of respiratory depression and death.
• Dextromethorphan, benzonatate, antihistamines, guaifenesin, and mucolytics show a lack of proven efficacy or insufficient data for pediatric use.
• Dextromethorphan may also contribute to respiratory depression.
• Honey and topical aromatic oils (camphor, menthol, eucalyptus) present limited efficacy data but a potentially greater safety margin.

Conclusions:

• Many common OTC cough and cold medications lack proven efficacy and carry significant safety risks for children.
• Alternative treatments such as honey and aromatic oils may offer a safer approach for managing acute pediatric cough, despite limited evidence.
• Further research is warranted to establish effective and safe treatments for acute cough in pediatric populations.